Other News

Oxford, UK, 5th May 2017: Physiomics is pleased to announce that it will attend BioTrinity 2017. BioTrinity is one of Europe’s leading Biopartnering and Investment Conferences, to be held on 8-10 May at the Novotel London West. In addition to participating in a number of partnering meetings, Physiomics will present an update on its technology at the conference on Tuesday 9th May. Dr Jim Millen, CEO,...

Physiomics to give an oral presentation on developments of the Virtual Tumour platform in drug resistance at the Seventh American Conference on Pharmacometrics (“ACoP7”) Physiomics plc (AIM: PYC), the Oxford, UK based systems biology Company, is pleased to announce that it is participating in the ACoP7 Meeting 2017, taking place at the Hyatt Regency Bellevue, Washington on 24-26 October 2016. Dr David Orrell, Principal Consultant, will...

We have an opportunity for a Senior PK/PF Modeller to join our technical team to work on projects related to drug development. Find more details at our careers page. ...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce the appointment of Hybridan LLP as joint broker with immediate effect. Please click here for full information.  ...

Dr Christophe Chassagnole, COO and Dr Eric Fernandez, Project Leader will be both present at PAGE 2016. Dr Fernandez will present on modelling radiation therapy in the poster session I on the 8th of June at 10:20 and Dr Christophe Chassagnole will present on the newest development of the Virtual Tumour in drug resistance in the poster session II on the 8th of June at 15:10. Please click here...

If you missed any of our past webinars, you can now view them online! Under the Publications menu, you can now find a new Webinars section. If you have further questions about our services or products, please contact us using this form or directly at info@physiomics-plc.com....

Physiomics plc is pleased to announce that it has appointed Professor Mark Middleton to its Scientific Advisory Board. Professor Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford. He is an eminent clinician with highly relevant clinical experience. Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research...

Dr Hugues Dolgos, Global Head, Quantitative Pharmacology & Drug Disposition, Merck Serono, is presenting at the Quantitative Systems Pharmacology meeting today in Basel, Switzerland. His presentation, entitled “Transforming Modeling & Simulation at Merck-Serono to Implement the Translational Medicine Strategy”, will include a section on Physiomics technology. ...

Physiomics plc is pleased to announce that it is participating in the American Association for Cancer Research Annual Meeting 2015, taking place at the Pennsylvania Convention Center, Philadelphia, Pennsylvania on 18-22 April 2015. Dr Frances Brightman will present on the application of the Virtual Tumour platform to predict agents targeting the PD-1/PD-L1 axis in combination with radiotherapy. ...

Dr Christophe Chassagnole will be speaking on Translational modelling of vemurafenib, selumetinib and docetaxel in metastatic melanoma with virtual tumour on Thursday 22nd January at 11:10am. For more information please visit www.pamm2015.com...